3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators
    26.
    发明公开
    3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators 失效
    3-亚苄基-2-二氢吲哚酮及其类似物作为酪氨酸激酶活性调节剂

    公开(公告)号:EP0934931A2

    公开(公告)日:1999-08-11

    申请号:EP99103667.4

    申请日:1996-06-05

    申请人: Sugen, Inc.

    IPC分类号: C07D209/34

    摘要: The present invention relates to compounds of the formulae
    wherein
    X is Br, Cl, F or I;
    wherein
    Z is Br, Cl, F, I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl;
    capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

    摘要翻译: 本发明涉及下式的化合物:其中X是Br,Cl,F或I; 其中Z是Br,Cl,F,I,甲基,乙基,正丙基,异丙基,正丁基,异丁基或叔丁基; 能够调节酪氨酸激酶信号转导以调节,调节和/或抑制异常细胞增殖。

    QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS
    28.
    发明公开
    QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS 失效
    喹唑啉和FARMAZEUTISCHE组合物

    公开(公告)号:EP0832073A1

    公开(公告)日:1998-04-01

    申请号:EP96917174.0

    申请日:1996-06-04

    申请人: Sugen, Inc.

    IPC分类号: A61K31 A61P35 A61P43 C07D239

    CPC分类号: C07D239/74

    摘要: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities. The present invention also provides pharmaceutical compositions and methods for inhibiting cell proliferation of differentiation and related disorders. Examples of such disorders include cancers, blood vessel proliferative disorders, psoriasis, hyperimmune response and fibrotic disorders. Example ofother disorders include the HER2 disorders, EGF disorders, IGFR disorders, PDGFR disorders, met disorders, SrC disorders, and KDR/FLK-1 disorders described herein. It is to be understood that compounds which are effective for diseases related to one TK will also likely be effective for diseases related to other TK's, especially those from the same family. Thus, for example, compounds shown to have good effect against Her2 are likely to also have good effect against other members of the Her family, i.e., EGFR, Her3,and Her4.